Third Harmonic Bio Ends Equity Plans, Files S-8 POS Amid Liquidation
Rhea-AI Filing Summary
Third Harmonic Bio, Inc. (THRD) has filed Post-Effective Amendment No. 1 to four previously effective Form S-8 registration statements (File Nos. 333-267445, 333-270935, 333-278232 and 333-286189). The amendments deregister all shares of common stock that remain unsold under the company’s 2019 Stock Incentive Plan, 2022 Equity Incentive Plan and 2022 Employee Stock Purchase Plan.
The action follows the company’s wind-down: the board adopted a Plan of Dissolution on Apr 10 2025, shareholders approved it on Jun 5 2025, and a Certificate of Dissolution was filed on Jul 31 2025, becoming effective immediately. In line with the plan, THRD has terminated all securities offerings and is amending the S-8 filings to remove any unsold securities from registration. The amendment was signed by Chief Financial & Business Officer Christopher Murphy; no additional signatures are required under Rule 478.
Positive
- None.
Negative
- Deregistration of all remaining unissued shares confirms there will be no further equity opportunities for investors.
- Certificate of Dissolution effective 31 Jul 2025 finalizes the company’s liquidation process.
Insights
TL;DR: THRD deregisters unsold S-8 shares after formal dissolution—mechanical step confirming company wind-down.
The filing is a housekeeping move that finalizes Third Harmonic Bio’s exit from the public markets. Once the certificate of dissolution became effective on 31 Jul 2025, the company was required to terminate outstanding registration statements and remove any securities that were never issued. Investors already knew of the liquidation plan (board approval 10 Apr 2025; shareholder approval 5 Jun 2025), so today’s amendment merely completes the regulatory checklist. While impactful in that it confirms no future equity issuance, the economic effect had been priced in when the dissolution was announced.